journal

Lancet Oncology

journal
https://read.qxmd.com/read/31928926/olaparib-plus-bevacizumab-improves-progression-free-survival-in-ovarian-cancer
#1
Elizabeth Gourd
No abstract text is available yet for this article.
January 9, 2020: Lancet Oncology
https://read.qxmd.com/read/31926806/artificial-intelligence-for-diagnosis-and-grading-of-prostate-cancer-in-biopsies-a-population-based-diagnostic-study
#2
Peter Ström, Kimmo Kartasalo, Henrik Olsson, Leslie Solorzano, Brett Delahunt, Daniel M Berney, David G Bostwick, Andrew J Evans, David J Grignon, Peter A Humphrey, Kenneth A Iczkowski, James G Kench, Glen Kristiansen, Theodorus H van der Kwast, Katia R M Leite, Jesse K McKenney, Jon Oxley, Chin-Chen Pan, Hemamali Samaratunga, John R Srigley, Hiroyuki Takahashi, Toyonori Tsuzuki, Murali Varma, Ming Zhou, Johan Lindberg, Cecilia Lindskog, Pekka Ruusuvuori, Carolina Wählby, Henrik Grönberg, Mattias Rantalainen, Lars Egevad, Martin Eklund
BACKGROUND: An increasing volume of prostate biopsies and a worldwide shortage of urological pathologists puts a strain on pathology departments. Additionally, the high intra-observer and inter-observer variability in grading can result in overtreatment and undertreatment of prostate cancer. To alleviate these problems, we aimed to develop an artificial intelligence (AI) system with clinically acceptable accuracy for prostate cancer detection, localisation, and Gleason grading. METHODS: We digitised 6682 slides from needle core biopsies from 976 randomly selected participants aged 50-69 in the Swedish prospective and population-based STHLM3 diagnostic study done between May 28, 2012, and Dec 30, 2014 (ISRCTN84445406), and another 271 from 93 men from outside the study...
January 8, 2020: Lancet Oncology
https://read.qxmd.com/read/31926805/automated-deep-learning-system-for-gleason-grading-of-prostate-cancer-using-biopsies-a-diagnostic-study
#3
Wouter Bulten, Hans Pinckaers, Hester van Boven, Robert Vink, Thomas de Bel, Bram van Ginneken, Jeroen van der Laak, Christina Hulsbergen-van de Kaa, Geert Litjens
BACKGROUND: The Gleason score is the strongest correlating predictor of recurrence for prostate cancer, but has substantial inter-observer variability, limiting its usefulness for individual patients. Specialised urological pathologists have greater concordance; however, such expertise is not widely available. Prostate cancer diagnostics could thus benefit from robust, reproducible Gleason grading. We aimed to investigate the potential of deep learning to perform automated Gleason grading of prostate biopsies...
January 8, 2020: Lancet Oncology
https://read.qxmd.com/read/31926804/deep-learning-approaches-for-gleason-grading-of-prostate-biopsies
#4
Anant Madabhushi, Michael D Feldman, Patrick Leo
No abstract text is available yet for this article.
January 8, 2020: Lancet Oncology
https://read.qxmd.com/read/31879221/genetic-susceptibility-to-natural-killer-t-cell-lymphoma
#5
Can Küçük
No abstract text is available yet for this article.
December 23, 2019: Lancet Oncology
https://read.qxmd.com/read/31879220/genetic-risk-of-extranodal-natural-killer-t-cell-lymphoma-a-genome-wide-association-study-in-multiple-populations
#6
Guo-Wang Lin, Caigang Xu, Kexin Chen, Hui-Qiang Huang, Jieping Chen, Bao Song, John K C Chan, Wenyu Li, Weiping Liu, Lee-Yung Shih, Wen-Yu Chuang, Won Seog Kim, Wen Tan, Rou-Jun Peng, Yurike Laurensia, Daryl Ming Zhe Cheah, DaChuan Huang, Chee Leong Cheng, Yi-Jiun Su, Soo-Yong Tan, Siok-Bian Ng, Tiffany Pooi Ling Tang, Kyudong Han, Vivien Ya-Fan Wang, Wei-Hua Jia, Zhong Pei, Ya-Jun Li, Song Gao, Yongyong Shi, Zhibin Hu, Furen Zhang, Ben Zhang, Yi-Xin Zeng, Hongbing Shen, Lin He, Choon Kiat Ong, Soon Thye Lim, Stephen Chanock, Yok-Lam Kwong, Dongxin Lin, Nathaniel Rothman, Chiea Chuen Khor, Qing Lan, Jin-Xin Bei
BACKGROUND: Extranodal natural killer T-cell lymphoma (NKTCL; nasal type) is an aggressive malignancy with a particularly high prevalence in Asian and Latin American populations. Epstein-Barr virus infection has a role in the pathogenesis of NKTCL, and HLA-DPB1 variants are risk factors for the disease. We aimed to identify additional novel genetic variants affecting risk of NKTCL. METHODS: We did a genome-wide association study of NKTCL in multiple populations from east Asia...
December 23, 2019: Lancet Oncology
https://read.qxmd.com/read/31870811/transcriptomic-signatures-related-to-the-obesity-paradox-in-patients-with-clear-cell-renal-cell-carcinoma-a-cohort-study
#7
Alejandro Sanchez, Helena Furberg, Fengshen Kuo, Lynda Vuong, Yasser Ged, Sujata Patil, Irina Ostrovnaya, Stacey Petruzella, Albert Reising, Parul Patel, Roy Mano, Jonathan Coleman, Paul Russo, Catherine H Liu, Andrew J Dannenberg, Timothy A Chan, Robert Motzer, Martin H Voss, A Ari Hakimi
BACKGROUND: Obesity is associated with an increased risk of developing clear cell renal cell carcinoma (RCC) but, paradoxically, obesity is also associated with improved oncological outcomes in this cancer. Because the biological mechanisms underlying this paradoxical association are poorly understood, we aimed to identify transcriptomic differences in primary tumour and peritumoral adipose tissue between obese patients and those at a normal weight. METHODS: In this cohort study, we assessed data from five independent clinical cohorts of patients with clear cell RCC aged 18 years and older...
December 20, 2019: Lancet Oncology
https://read.qxmd.com/read/31870810/unlocking-the-secret-of-the-obesity-paradox-in-renal-tumours
#8
Matteo Santoni, Alessio Cortellini, Sebastiano Buti
No abstract text is available yet for this article.
December 20, 2019: Lancet Oncology
https://read.qxmd.com/read/31866168/san-antonio-breast-cancer-symposium-2019
#9
Katherine Gourd
No abstract text is available yet for this article.
December 19, 2019: Lancet Oncology
https://read.qxmd.com/read/31859247/cdk4-6-inhibitors-in-breast-cancer-one-more-step-towards-reduced-mortality
#10
Giuseppe Curigliano, Sibylle Loibl
No abstract text is available yet for this article.
December 16, 2019: Lancet Oncology
https://read.qxmd.com/read/31859246/cdk4-6-inhibitor-treatment-for-patients-with-hormone-receptor-positive-her2-negative-advanced-or-metastatic-breast-cancer-a-us-food-and-drug-administration-pooled-analysis
#11
Jennifer J Gao, Joyce Cheng, Erik Bloomquist, Jacquelyn Sanchez, Suparna B Wedam, Harpreet Singh, Laleh Amiri-Kordestani, Amna Ibrahim, Rajeshwari Sridhara, Kirsten B Goldberg, Marc R Theoret, Paul G Kluetz, Gideon M Blumenthal, Richard Pazdur, Julia A Beaver, Tatiana M Prowell
BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are indicated with endocrine therapy as first-line or second-line treatment for hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer. We aimed to investigate the benefit of adding CDKIs to endocrine therapy in patients whose tumours might have differing degrees of endocrine sensitivity. METHODS: We pooled individual patient data from all phase 3 randomised breast cancer trials of CDKIs plus endocrine therapy submitted to the US Food and Drug Administration before Jan 1, 2019, in support of marketing applications...
December 16, 2019: Lancet Oncology
https://read.qxmd.com/read/31859245/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two-arm-randomised-open-label-phase-2-study
#12
Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Nikoletta Lendvai, Douglas Sborov, Attaya Suvannasankha, Katja Weisel, Lionel Karlin, Edward Libby, Bertrand Arnulf, Thierry Facon, Cyrille Hulin, K Martin Kortüm, Paula Rodríguez-Otero, Saad Z Usmani, Parameswaran Hari, Rachid Baz, Hang Quach, Philippe Moreau, Peter M Voorhees, Ira Gupta, Axel Hoos, Eric Zhi, January Baron, Trisha Piontek, Eric Lewis, Roxanne C Jewell, Elisha J Dettman, Rakesh Popat, Simona Degli Esposti, Joanna Opalinska, Paul Richardson, Adam D Cohen
BACKGROUND: Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma. We further investigated the safety and activity of belantamab mafodotin in the DREAMM-2 study. METHODS: DREAMM-2 is an open-label, two-arm, phase 2 study done at 58 multiple myeloma specialty centres in eight countries. Patients (aged ≥18 years) with relapsed or refractory multiple myeloma with disease progression after three or more lines of therapy and who were refractory to immunomodulatory drugs and proteasome inhibitors, and refractory or intolerant (or both) to an anti-CD38 monoclonal antibody with an Eastern Cooperative Oncology Group performance status of 0-2 were recruited, centrally randomly assigned (1:1) with permuted blocks (block size 4), and stratified by previous lines of therapy (≤4 vs >4) and cytogenetic features to receive 2·5 mg/kg or 3·4 mg/kg belantamab mafodotin via intravenous infusion every 3 weeks on day 1 of each cycle until disease progression or unacceptable toxicity...
December 16, 2019: Lancet Oncology
https://read.qxmd.com/read/31839270/2019-ash-annual-meeting
#13
Farhat Yaqub
No abstract text is available yet for this article.
December 12, 2019: Lancet Oncology
https://read.qxmd.com/read/31839269/osimertinib-for-leptomeningeal-metastases-in-nsclc
#14
Elizabeth Gourd
No abstract text is available yet for this article.
December 12, 2019: Lancet Oncology
https://read.qxmd.com/read/31838015/entrectinib-in-ros1-fusion-positive-non-small-cell-lung-cancer-integrated-analysis-of-three-phase-1-2-trials
#15
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf, Takashi Seto, Byoung Chul Cho, Manish R Patel, Chao-Hua Chiu, Thomas John, Koichi Goto, Christos S Karapetis, Hendrick-Tobias Arkenau, Sang-We Kim, Yuichiro Ohe, Yu-Chung Li, Young K Chae, Christine H Chung, Gregory A Otterson, Haruyasu Murakami, Chia-Chi Lin, Daniel S W Tan, Hans Prenen, Todd Riehl, Edna Chow-Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R Wilson, Robert C Doebele
BACKGROUND: Recurrent gene fusions, such as ROS1 fusions, are oncogenic drivers of various cancers, including non-small-cell lung cancer (NSCLC). Up to 36% of patients with ROS1 fusion-positive NSCLC have brain metastases at the diagnosis of advanced disease. Entrectinib is a ROS1 inhibitor that has been designed to effectively penetrate and remain in the CNS. We explored the use of entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive NSCLC. METHODS: We did an integrated analysis of three ongoing phase 1 or 2 trials of entrectinib (ALKA-372-001, STARTRK-1, and STARTRK-2)...
December 11, 2019: Lancet Oncology
https://read.qxmd.com/read/31838014/time-for-a-shift-in-molecular-down-staging-in-luminal-breast-cancer
#16
Massimo Cristofanilli
No abstract text is available yet for this article.
December 11, 2019: Lancet Oncology
https://read.qxmd.com/read/31838013/the-role-of-self-management-in-cancer-survivorship-care
#17
Afaf Girgis
No abstract text is available yet for this article.
December 11, 2019: Lancet Oncology
https://read.qxmd.com/read/31838012/time-to-re-think-the-olanzapine-dose
#18
Alex Molassiotis
No abstract text is available yet for this article.
December 11, 2019: Lancet Oncology
https://read.qxmd.com/read/31838011/olanzapine-5-mg-plus-standard-antiemetic-therapy-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-j-force-a-multicentre-randomised-double-blind-placebo-controlled-phase-3-trial
#19
Hironobu Hashimoto, Masakazu Abe, Osamu Tokuyama, Hideaki Mizutani, Yosuke Uchitomi, Takuhiro Yamaguchi, Yukari Hoshina, Yasuhiko Sakata, Takako Yanai Takahashi, Kazuhisa Nakashima, Masahiko Nakao, Daisuke Takei, Sadamoto Zenda, Koki Mizukami, Satoru Iwasa, Michiru Sakurai, Noboru Yamamoto, Yuichiro Ohe
BACKGROUND: Olanzapine 10 mg added to standard antiemetic therapy including aprepitant, palonosetron, and dexamethasone has been recommended for the prevention of chemotherapy-induced nausea and vomiting. Guidelines suggest that a dose reduction to 5 mg should be considered to prevent sedation. In several phase 2 studies, olanzapine 5 mg has shown equivalent activity to olanzapine 10 mg and a favourable safety profile in relation to somnolence. We evaluated the efficacy of olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting caused by cisplatin-based chemotherapy...
December 11, 2019: Lancet Oncology
https://read.qxmd.com/read/31838010/ribociclib-plus-letrozole-versus-chemotherapy-for-postmenopausal-women-with-hormone-receptor-positive-her2-negative-luminal-b-breast-cancer-coralleen-an-open-label-multicentre-randomised-phase-2-trial
#20
Aleix Prat, Cristina Saura, Tomás Pascual, Cristina Hernando, Montserrat Muñoz, Laia Paré, Blanca González Farré, Pedro L Fernández, Patricia Galván, Núria Chic, Xavier González Farré, Mafalda Oliveira, Miguel Gil-Gil, Miriam Arumi, Neus Ferrer, Alvaro Montaño, Yann Izarzugaza, Antonio Llombart-Cussac, Raquel Bratos, Santiago González Santiago, Eduardo Martínez, Sergio Hoyos, Beatriz Rojas, Juan Antonio Virizuela, Vanesa Ortega, Rafael López, Pamela Céliz, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá
BACKGROUND: In hormone receptor-positive, HER2-negative early stage breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition in combination with endocrine therapy could represent an alternative to multiagent chemotherapy. We aimed to evaluate the biological and clinical activity of neoadjuvant ribociclib plus letrozole in the luminal B subtype of early stage breast cancer. METHODS: CORALLEEN is a parallel-arm, multicentre, randomised, open-label, phase 2 trial completed across 21 hospitals in Spain...
December 11, 2019: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"